Research programme: bone-targeted mTOR inhibitors - ARIAD

Drug Profile

Research programme: bone-targeted mTOR inhibitors - ARIAD

Alternative Names: AP 23675; AP 23841; AP 24170

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator ARIAD Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bone cancer

Most Recent Events

  • 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
  • 08 Jul 2009 No development reported - Preclinical for Bone cancer in USA (unspecified route)
  • 01 May 2006 Data presented at the 97th Annual Meeting of the American Association for Cancer Research (AACR-2006) have been added to the pharmacokinetics and Cancer pharmacodynamics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top